The APA Guideline stresses the importance ... may be indicated for catatonic schizophrenia, treatment-resistant schizophrenia, or severe depression that cannot be managed with medications.

The management of treatment resistant schizophrenia does remain controversial [48] but guidelines have some consistency in supporting use of clozapine [49,50] and psychosocial approaches for which ...

Welcome to the AbbVie third quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms.

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients. Treatment adherence is a big challenge for patients with schizophrenia ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to ...

serotonergic and adrenergic receptors – failed to improve the positive and negative schizophrenia symptom scale (PANSS) compared to conventional therapy in patients with treatment-resistant ...

Auditory verbal hallucinations are one of the hallmarks of psychosis, particularly in people with schizophrenia, which affects 24 million people globally. These voices often bully or abuse the ...

Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of ...

Most kids with attention issues won't go on to develop serious psychiatric conditions like psychosis or schizophrenia ... in adults who undergo the same treatment, a large, NIH-funded study.